X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN LTD vs ORCHID PHARMA LTD - Comparison Results

LUPIN LTD    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN LTD ORCHID PHARMA LTD LUPIN LTD/
ORCHID PHARMA LTD
 
P/E (TTM) x 29.4 -0.1 - View Chart
P/BV x 2.8 0.1 2,578.1% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 LUPIN LTD   ORCHID PHARMA LTD
EQUITY SHARE DATA
    LUPIN LTD
Mar-18
ORCHID PHARMA LTD
Sep-13
LUPIN LTD/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,465194 755.2%   
Low Rs72735 2,077.4%   
Sales per share (Unadj.) Rs349.6276.5 126.4%  
Earnings per share (Unadj.) Rs5.6-79.2 -7.0%  
Cash flow per share (Unadj.) Rs29.6-43.5 -68.1%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs300.353.9 556.8%  
Shares outstanding (eoy) m452.0870.45 641.7%   
Bonus/Rights/Conversions ESOPSESOP-  
Price / Sales ratio x3.10.4 757.0%   
Avg P/E ratio x197.2-1.4 -13,642.5%  
P/CF ratio (eoy) x37.1-2.6 -1,406.3%  
Price / Book Value ratio x3.62.1 171.9%  
Dividend payout %90.00-   
Avg Mkt Cap Rs m495,5028,067 6,142.7%   
No. of employees `00017.02.8 608.6%   
Total wages/salary Rs m28,6472,527 1,133.6%   
Avg. sales/employee Rs Th9,273.66,956.1 133.3%   
Avg. wages/employee Rs Th1,681.0902.5 186.3%   
Avg. net profit/employee Rs Th147.4-1,993.0 -7.4%   
INCOME DATA
Net Sales Rs m158,04219,477 811.4%  
Other income Rs m1,504407 369.2%   
Total revenues Rs m159,54519,884 802.4%   
Gross profit Rs m31,4751,103 2,854.6%  
Depreciation Rs m10,8592,519 431.0%   
Interest Rs m2,0445,227 39.1%   
Profit before tax Rs m20,076-6,236 -321.9%   
Minority Interest Rs m-7120 -359.9%   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644511 -2,865.7%   
Tax Rs m2,885-125 -2,304.0%   
Profit after tax Rs m2,513-5,580 -45.0%  
Gross profit margin %19.95.7 351.8%  
Effective tax rate %14.42.0 715.7%   
Net profit margin %1.6-28.7 -5.5%  
BALANCE SHEET DATA
Current assets Rs m122,09511,014 1,108.5%   
Current liabilities Rs m50,95632,060 158.9%   
Net working cap to sales %45.0-108.1 -41.7%  
Current ratio x2.40.3 697.5%  
Inventory Days Days8595 89.2%  
Debtors Days Days12034 357.4%  
Net fixed assets Rs m129,87629,440 441.2%   
Share capital Rs m904705 128.3%   
"Free" reserves Rs m134,8662,043 6,602.7%   
Net worth Rs m135,7713,800 3,573.0%   
Long term debt Rs m64,2459,018 712.4%   
Total assets Rs m263,05446,510 565.6%  
Interest coverage x10.8-0.2 -5,605.1%   
Debt to equity ratio x0.52.4 19.9%  
Sales to assets ratio x0.60.4 143.5%   
Return on assets %1.7-0.8 -227.9%  
Return on equity %1.9-146.9 -1.3%  
Return on capital %3.7-3.7 -99.6%  
Exports to sales %037.9 0.0%   
Imports to sales %022.6 0.0%   
Exports (fob) Rs mNA7,378 0.0%   
Imports (cif) Rs mNA4,406 0.0%   
Fx inflow Rs m53,1417,513 707.3%   
Fx outflow Rs m19,3355,649 342.3%   
Net fx Rs m33,8071,865 1,813.2%   
CASH FLOW
From Operations Rs m17,5121,682 1,041.3%  
From Investments Rs m-14,073-9,860 142.7%  
From Financial Activity Rs m-14,9216,644 -224.6%  
Net Cashflow Rs m-11,482-1,535 748.0%  

Share Holding

Indian Promoters % 46.6 32.3 144.3%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 4.6 245.7%  
FIIs % 31.9 3.3 966.7%  
ADR/GDR % 0.0 4.6 -  
Free float % 10.1 55.3 18.3%  
Shareholders   98,259 84,811 115.9%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN LTD With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  ELDER PHARMA  NOVARTIS  PANACEA BIOTECH  

Compare LUPIN LTD With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 307 Points Higher; Metal and Oil & Gas Stocks Witness Buying(Closing)

Indian share markets traded on a positive note throughout the day and ended on a strong note. Gains were seen in the metal sector.

Related Views on News

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)

Dec 6, 2018

My latest StockSelect recommendation ticks all the boxes of a great safe stock.

Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)

Dec 11, 2018

RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.

Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)

Dec 7, 2018

This stock has corrected 30% from peak and looks attractive at these valuations.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)

Dec 5, 2018

PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN LTD SHARE PRICE


Dec 17, 2018 (Close)

TRACK LUPIN LTD

  • Track your investment in LUPIN LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

LUPIN LTD - FDC LTD. COMPARISON

COMPARE LUPIN LTD WITH

MARKET STATS